Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $220,974.75 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 2,565 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of $86.15, for a total value of $220,974.75. Following the sale, the executive vice president directly owned 123,478 shares in the company, valued at approximately $10,637,629.70. This trade represents a 2.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sadie Stern also recently made the following trade(s):

• On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The shares were sold at an average price of $88.37, for a total value of $226,669.05.

DexCom Trading Down 1.0%

DXCM opened at $85.36 on Friday. The stock has a market capitalization of $32.21 billion, a price-to-earnings ratio of 33.74, a P/E/G ratio of 1.44 and a beta of 1.48. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The company has a 50-day simple moving average of $86.70 and a 200 day simple moving average of $74.55.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.48 EPS. Analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently bought and sold shares of DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in DexCom by 15.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after buying an additional 1,515,702 shares during the last quarter. Janus Henderson Group PLC grew its holdings in DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after acquiring an additional 645,534 shares during the last quarter. Legal & General Group Plc bought a new stake in DexCom during the 2nd quarter worth approximately $173,237,000. Arrowstreet Capital Limited Partnership increased its position in DexCom by 100.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock valued at $159,832,000 after acquiring an additional 1,275,142 shares during the period. Finally, Deutsche Bank AG acquired a new position in DexCom in the 2nd quarter valued at approximately $164,035,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on DXCM. Stifel Nicolaus set a $95.00 price target on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Citigroup restated a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Argus raised their price objective on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective on the stock. Finally, Mizuho boosted their target price on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.74.

DexCom Company Profile

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.